The Affiliated People's Hospital of Ningbo University
17
11
11
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 17 trials
100.0%
+13.5% vs industry average
18%
3 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)
Role: collaborator
SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases
Role: collaborator
AI-Powered Precision Decision-Making for Pancreatic Diseases
Role: collaborator
Safety and Efficacy of Ventricular Irrigation for Ventriculitis
Role: collaborator
Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen
Role: lead
SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer
Role: collaborator
Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
Role: lead
InsightPFA Trial of the LotosPFA Catheter
Role: collaborator
Pronase in Improving Endoscopic Mucosal Clarity During Colonoscopy for Patients with Colitis
Role: collaborator
Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer
Role: collaborator
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
Role: lead
A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML
Role: collaborator
Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies
Role: lead
Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies
Role: lead
Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome
Role: collaborator
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
Role: lead
Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT
Role: collaborator
All 17 trials loaded